An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
NCT07764146
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alzheimer s Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 30 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Voyager Therapeutics
- Last updated on ClinicalTrials.gov
- September 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- K2 Medical Research, LLC · Maitland, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.